Skip to main content
. 2021 Jul 6;12:4015. doi: 10.1038/s41467-021-24265-8

Fig. 1. Study types and allocation into sex/gender (S/G) attention groups for the COVID-19 sample.

Fig. 1

The left-hand (green) panel shows the distribution of the 4420 identified studies across study types. We created the (Pharmacological) RCT label following the procedure outlined in Methods section, the other classifications are taken from ClinicalTrials.gov. The right-hand panel (blue) shows the distribution of studies across the various mutually exclusive sex/gender groups we defined (see Methods section). In the ‘Some S/G mention’ set there is a hierarchy. The most extensive consideration was sex/gender as an analytical variable and after that sex/gender matching/representation, followed by explicit statements of intent to record or report participant sex/gender. Finally, the ‘Recruitment Only’ contains those studies whose only sex/gender mention was in a recruiting context. We allocated the studies to one of the categories based on the highest category of S/G consideration. For instance, if they reported attention to S/G in analysis and recruiting, we only counted them in analysis.